US Sales Of RSV Vaccines From GSK, Pfizer Are Down After Regulators Narrowed Targeted Age Group

October 09, 2024

Reuters (10/8, Erman) reports, “U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and said it was a once-in-a-lifetime shot for now, excluding millions of people who got one last year.” A number of “independent pharmacists said demand during the autumn vaccination season for respiratory syncytial virus shots has fallen as much as two-thirds from a year ago.” Volumes that have been “reported by healthcare data company IQVIA and published in several Wall Street analyst notes roughly match that mark.”